Evotec Announces Sweeping Restructuring Amid Grim Financial Forecast

Evotec shares hit 52-week low as cost-cutting plan and lowered 2026 financial guidance raise investor concerns over the biotech firm's transitional year.

The Hamburg-based biotechnology firm Evotec SE has initiated a severe cost-cutting strategy in an effort to steer the company toward long-term stability. However, the simultaneous release of a subdued financial outlook for the current year has severely dampened investor sentiment, raising questions about the plan's efficacy.

Market Reaction and Financial Guidance

Investor response to the announcements was swift and punitive. On Tuesday, Evotec's shares plunged to a new 52-week low of precisely €4.61. This decline extends a one-month loss of 26%, with the stock now trading well below its 50-day moving average of €6.05, highlighting persistent technical weakness.

The negative sentiment was primarily fueled by a disappointing forecast for 2026. Management has explicitly labeled the current year a transitional period. The company now anticipates revenue to fall between €700 million and €780 million, a noticeable drop from the preliminary figure of €788 million in 2025. Adjusted EBITDA is also projected to be weaker, expected in a range of €0 to €40 million, compared to the €41 million achieved the previous year.

The "Horizon" Transformation Plan

Dubbed "Horizon," the newly unveiled restructuring program is designed to consolidate research competencies and achieve annual savings of approximately €75 million by the end of 2027. To reach this goal, the company will implement radical measures.

The plan involves a significant reduction of its global workforce, with up to 800 positions slated for elimination. Furthermore, Evotec will streamline its site network over the next two years, reducing its locations from 14 to 10. This consolidation includes the complete closure of its Munich site.

These cuts come with a substantial upfront cost. The company estimates that implementing the restructuring will incur expenses of around €100 million through 2028.

A Pivotal Transition Year

While this drastic overhaul is viewed as a necessary step to restore long-term profitability, it demands considerable patience from shareholders during the challenging transition period ahead. Evotec is scheduled to release its full-year results in April, at which time it will provide further details on its financial position and the precise timeline for the site closures.